DiaSys Corporation Announces $420,000 in Orders from Hua-Sin Science Company Limited.

WATERBURY, Conn. -- DiaSys Corporation (AMEX:DYX) a global healthcare products company announced today that it has received confirmed orders from its Far East trading partner Hua-Sin Science Company Limited totaling $420,000 for the Chinese market over the coming nine-month period. The order is across the product line of the company's workstations. Hua-Sin will purchase both R/S 2003 and R/S 500 urinalysis workstations and FE-2 Parasitology workstations. The R/S 500 was designed specifically for the Chinese market to address the need for lower volume hospitals, which represent the majority of Chinese hospitals. It received its official registration from the Chinese government earlier this year.

DiaSys Corporation renewed its distribution agreement with Hua-Sin Science Company Limited in 2003. Sales of the company's products to the Far East slowed dramatically following the outbreak of Severe Acute Respiratory Syndrome (SARS) in the second calendar quarter of 2003. Sales to Hua-Sin for the fiscal year June 1, 2003 to May 31, 2004 totaled $ 191,801 and sales for the comparable nine-month period from July 1, 2003 to March 31, 2004 totaled $ 123,850. Over the following nine-months this order of $420,000 represents an increase in sales to China of $ 296,150 or 239% from last years nine-month comparable period.

Morris Silverman, Chairman of DiaSys Corporation said, "Our business in China has represented only a part of a market that has greater potential for the company. Based on enhancing our partnership with Hua-Sin, we believe that DiaSys will capture a larger part of the rapidly growing Chinese market."

Gregory Witchel, Chief Executive Officer of DiaSys Corporation stated " We are pleased that our partner in the Far East has now not only reconstituted their historical sales level, but has increased their orders to DiaSys Corporation. We look forward to a record twelve months in Far East sales. The company and Hua-Sin are now working on a number of new business initiatives that should greatly enhance sales and cash flow to both companies. I look forward to returning to China at the end of this summer to begin expediting these new opportunities."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.